EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hemin‐induced platelet activation is regulated by the ACKR3 chemokine surface receptor and has implications for passivation of vulnerable atherosclerotic plaques

Zoi Laspa, Valerie Dicenta-Baunach, David Schaale, Manuel Sigle, Ravi Hochuli, Tatsiana Castor, Alp Bayrak, Tobias Harm, Karin Anne Lydia Müller, Thanigaimalai Pillaiyar, Stefan Laufer, Anne-Katrin Rohlfing und 1 weitere

The FEBS Journal · 2024

DOI: 10.1111/febs.17294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, 2024. Verfasst von Zoi Laspa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Angiology, University Hospital Tübingen, University Tübingen, Germany. Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, Hemin, Platelet Activation, Blood Platelets. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung, Deutsche Forschungsgemeinschaft, Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In vulnerable atherosclerotic plaques, intraplaque hemorrhages (IPH) result in hemolysis of red blood cells and release of hemoglobin and free hemin. Hemin activates platelets and leads to thrombosis. Agonism of the inhibitory platelet receptor ACKR3 inhibits hemin‐dependent platelet activation and thrombus formation. To characterize the effect of hemin and ACKR3 agonism on isolated human platelets, multi‐color flow cytometry and classical experimental setup such as light transmission aggregometry and a flow chamber assay were used. Hemin induces platelet aggregation and ex vivo platelet‐dependent thrombus formation on immobilized collagen under a low shear rate of 500 s −1 , indicating that free hemin is a strong activator of platelet‐dependent thrombosis. Recently, we described that ACKR3 is a prominent inhibitory receptor of platelet activation. Specific ACKR3 agonists but not conventional antiplatelet compounds such as COX‐1 inhibitor (indometacin), ADP‐receptor blocker (cangrelor), or PAR1 inhibitor (ML161) inhibit both hemin‐dependent aggregation and thrombus formation. To further characterize the effect of hemin on platelet subpopulations, we established a multi‐color flow cytometry assay. We found that hemin induces procoagulant (CD42b pos /PAC‐1 neg /AnnexinV pos ), aggregatory (CD42b pos /PAC‐1 pos /AnnexinV neg ), and inflammatory (CD42b pos /CXCR4 pos /ACKR3 pos /AnnexinV pos ) platelet subpopulations. Treatment with ACKR3 agonists significantly decreased the formation of procoagulant and ACKR3 pos platelets in response to hemin. We conclude that hemin is a strong activator for the formation of procoagulant platelets and thrombus formation which is dependent on the function of ACKR3. Activation of ACKR3 using specific agonists may offer a therapeutic strategy to regulate the vulnerability of atherosclerotic plaques in areas of IPH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plaque, AtheroscleroticHeminPlatelet ActivationBlood PlateletsPlatelet AggregationHumansReceptors, CXCRThrombosis

Stichwörter der Autor:innen

ACKR3heminintraplaque hemorrhage (IPH)multi‐color flow cytometryplatelets

Substanzen

HeminACKR3 protein, humanReceptors, CXCR

Autor:innen und Institutionen

  • Department of Cardiology and Angiology, University Hospital Tübingen, University Tübingen, Germany.
  • Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, University Tübingen, Germany.
  • Tübingen Center for Academic Drug Discovery & Development (TüCAD2), Germany.
  • iFIT Cluster of Excellence EXC 2180 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Germany.

ORCID-Profile: Meinrad Paul Gawaz

Förderung

  • Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung
  • Deutsche Forschungsgemeinschaft
  • Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung.

Zitieren

APA

Laspa, Z., Dicenta-Baunach, V., Schaale, D., Sigle, M., Hochuli, R., Castor, T., Bayrak, A., Harm, T., Müller, K. A. L., Pillaiyar, T., Laufer, S., Rohlfing, A. K., & Gawaz, M. P. (2024). Hemin‐induced platelet activation is regulated by the ACKR3 chemokine surface receptor and has implications for passivation of vulnerable atherosclerotic plaques. The FEBS Journal. https://doi.org/10.1111/febs.17294

Vancouver

Laspa Z, Dicenta-Baunach V, Schaale D, Sigle M, Hochuli R, Castor T, et al. Hemin‐induced platelet activation is regulated by the ACKR3 chemokine surface receptor and has implications for passivation of vulnerable atherosclerotic plaques. The FEBS Journal. 2024. doi:10.1111/febs.17294

BibTeX
@article{Laspa2024,
  author = {Laspa, Zoi and Dicenta-Baunach, Valerie and Schaale, David and Sigle, Manuel and Hochuli, Ravi and Castor, Tatsiana and Bayrak, Alp and Harm, Tobias and Müller, Karin Anne Lydia and Pillaiyar, Thanigaimalai and Laufer, Stefan and Rohlfing, Anne-Katrin and Gawaz, Meinrad Paul},
  title = {Hemin‐induced platelet activation is regulated by the ACKR3 chemokine surface receptor and has implications for passivation of vulnerable atherosclerotic plaques},
  journal = {The FEBS Journal},
  year = {2024},
  doi = {10.1111/febs.17294}
}
Kostenlos starten →